Generics 65

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Linagliptin manufacturers

65 products found

Filters

65 products found

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
Reference product: Trajenta
Manufacturer #16163
As a result of a strategic agreement with a company delivering an attractive high-quality portfolio with European supply, it is a trustworthy B2B partner with more than 30 years of experience in the out-licensing business model. The organization is a reliable commercial partner that takes a customer-centric approach and strives for long-term partnership development to secure market success.

Manufacturer usually replies in 6 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Bolivia , Chile , Colombia , Costa Rica , Dominican Republic , El Salvador , Guatemala , Honduras , Nicaragua , Panama , Paraguay , Peru , Ukraine , Uruguay , Venezuela
Comments
DCP ongoing
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

Manufacturer usually replies in 5 days

linagliptin

Oral solution 5 mg/5 ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q4 2024
Manufacturer #8593
It is a private R&D and business development organization established in the 2000s, specializing in the design and development of new pharmaceutical products worldwide. They have an average of 5-6 new developments per year, an average of 8-10 DCPs per year, more than 60 dossier updates in the last 10 years, they have more than 3 valid and approved patent applications, and approximately 140 MAs worldwide.

Manufacturer usually replies in 2 days

linagliptin + metformin

Tablets, film coated 2.5 mg/850 mg , 2.5 mg/1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Chile , Turkey , Vietnam , Panama
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Chile , Panama , Turkey , Vietnam
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Armenia , Cyprus , Greece , Israel , Kazakhstan , Kosovo , Libya , Tajikistan , Uzbekistan , Vietnam
Comments
Dossier availability date: Q1 2024
Manufacturer #17046

It is one of the fastest-growing pharmaceutical firms and a top investor in Rx and Healthcare solutions. The company has been awarded several prizes for its performance and growing business units and has recently been characterized as one of the local economy gems. Based in Europe.

Manufacturer usually replies in 6 days

linagliptin + metformin

Tablets, film coated 2.5 mg + 850 mg , 2.5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Albania , Armenia , Azerbaijan , Greece , Iraq , Israel , Kazakhstan , Kosovo , Libya , Tajikistan , Uzbekistan , Vietnam
Comments
Dossier availability date: Q3 2024
Manufacturer #17046

It is one of the fastest-growing pharmaceutical firms and a top investor in Rx and Healthcare solutions. The company has been awarded several prizes for its performance and growing business units and has recently been characterized as one of the local economy gems. Based in Europe.

Manufacturer usually replies in 6 days

linagliptin + metformin

Tablets, film coated 2.5 mg + 1000 mg, 2.5 mg + 850 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 9 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 9 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

linagliptin

Tablets 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Trajenta® (Boehringer Ingelheim International GmbH)
Manufacturer #10578

Manufacturer usually replies in 6 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q3 2024
Manufacturer #519

Manufacturer usually replies in 6 days

linagliptin + metformin

Tablets, film coated 2.5 mg + 850 mg, 2.5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q3 2024
Manufacturer #519

Manufacturer usually replies in 6 days

linagliptin + losartan

Tablets, film coated 2.5 mg + 850 mg, 2.5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

linagliptin + metformin

Tablets 2.5 mg + 850 mg, 2.5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q1 2024
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

linagliptin

Tablets 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q1 2024
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

linagliptin

Tablets, film coated 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

linagliptin

Tablets 5 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #358
A pharmaceutical manufacturer based in the EU that is active in 70+ countries worldwide selling its products in the EU, Australia, Pacific region, and Asia for 30+ years. The company owns several manufacturing plants that comply with EU GMP requirements with production facilities for Rx products, OTC products, nutraceuticals, and medical devices. Its key therapy areas are diabetology, oncology, and neuropsychiatry. The company possesses several R&D centers with hundreds of patents and provides e-CTD format dossiers.

Manufacturer usually replies in 23 days

linagliptin

Tablets 5 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
Dossier availability date: Q3 2024
Manufacturer #437
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products in Europe, North America, LATAM, Africa, Middle East, and Asia for 40+ years. Main therapeutics areas include the nervous system, cardiometabolic, and women’s health. The company's production lines are GMP-compliant. The main dosage forms are solid, semi-solid, liquid, and suspension. The company owns branches in the EU, Africa, and LATAM.

Manufacturer usually replies in 11 days

linagliptin + losartan

Tablets, film coated 2.5 mg + 850 mg , 2.5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

Want to view all 65 products? Create your free account today!

What is the Linagliptin drug?

Linagliptin is a DPP-4 inhibitor. Linagliptin works in two different ways; it helps the pancreas to produce more insulin and the liver to produce less sugar. The combination of those two actions lower the blood sugar in the patient. Linagliptin is a medication used to treat diabetes mellitus type 2; it works in addition to diet and exercise. The FDA in the US approved the medical use of the Linagliptin drug in 2011.

Linagliptin manufacturers and wholesalers:

Boehringer Ingelheim developed Linagliptin. One of its brand names is Tradjenta. Linagliptin suppliers market it in the form of a 5 mg oral film-coated tablet. Linagliptin is a globally found medication.

Linagliptin for sales:

In the US, Linagliptin's price is $16 per 5 mg tablet. For a month supply, the wholesale cost is about $391 whereas in the United Kingdom, for the same amount, one month, Linagliptin costs about £ 33.26.
On Pipelinepharma pharmaceutical market place, Linagliptin is most available from the European Union, India, and Bangladesh. The online platform helps the distributors to find qualified Linagliptin manufacturers globally, ensuring you they are not fraudulent websites. Using the integrated search engine of the marketplace, you can find a list of many pharmaceutical products for sale, including Linagliptin. Each Linagliptin manufacturer or supplier product description encompasses lots of information about the medication such as form, dose, manufacturing site approvals, and regulatory status. Then using the simple one-click contact form, you can enquire about the supply price if none are listed and place an order or send inquiries to companies no matter where they are in the world. Not only is this marketplace good news for distributors and other buyers, but wholesale sellers and manufacturers benefit as well. They can register and list an unlimited number of pharmaceutical products free of charge.

How to use Linagliptin drugs?

To treat diabetes - type 2, an adult patient should take 5 mg orally once a day. Linagliptin can be taken with or without food, but it is advised to take the medication at the same time of the day. Taking the Linagliptin drug can cause some side effects, such as anxiety, hypoglycemia, blurred vision, chills, cold sweats, confusion, and cool, pale skin. If patients had or have problems with their pancreas, they should not take Linagliptin. The Linagliptin must be stored at room temperature, away from humidity and heat. Keep it out of reach of children.